The two companies have been working together since 2017, and, in 2021, they agreed to collaborate on NM26, a bispecific ...

The path from a scientist’s initial idea to a new medicine that can save lives is a complex and often lengthy process. It ...

Risking Preclinical Toxicology Studies  Preclinical toxicology studies face a significant challenge: animal models cannot self-report side effects. This limitation proves particularly problematic when ...

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...

Evidence has been growing to suggest that tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, poses risks to the developing fetus by impacting brain development. Now a new ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

A new drug strategy that regulates the tumor immune ... the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights ...

The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor ...

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.